Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies

Medicine and Dentistry

• Programmed Cell Death 100%
• Antibody 80%
• Biological Marker 60%
• Nodular Melanoma 60%
• Drug 40%
• Chemotherapeutic Agent 40%
• Serum 20%
• Lymphocyte 20%
• Neoplasm 20%
• Adverse Event 20%
• Combination Therapy 20%
• Microsatellite Instability 20%
• Lactate Dehydrogenase 20%
• Ligand 20%
• Chemokine 20%
• Development 20%
• Melanoma Cell 20%
• DNA Mismatch Repair 20%
• Nivolumab 20%
• Pembrolizumab 20%
• Patient 20%
• Marker 20%
• Assay 20%
• Eosinophil 20%
• Neutrophil 20%
• Macrophage 20%
• Blood 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Antibody 80%
• Biological Marker 60%
• Melanoma 60%
• Drug 40%
• Adverse Event 20%
• Lactate Dehydrogenase 20%
• Ligand 20%
• Neoplasm 20%
• Chemokine 20%
• Nivolumab 20%
• Pembrolizumab 20%